Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2012

01.10.2012 | Short Communication

FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis

verfasst von: Cristina Nanni, Luca Boriani, Caterina Salvadori, Eleonora Zamparini, Giada Rorato, Valentina Ambrosini, Alessandro Gasbarrini, Fabio Tumietto, Francesco Cristini, Luigia Scudeller, Stefano Boriani, Pierluigi Viale, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Antibiotic therapy in patients affected by discitis is often empirical. Therefore, early evaluation of response to therapy is important. In many patients inflammatory indexes are low during all the phases of the diseases or are altered by concomitant diseases. The aim of the study was to assess the possible role of FDG PET/CT for the early evaluation of response to therapy in patients affected by infective discitis, in comparison to C-reactive protein (CRP) serum levels.

Methods

Enrolled in the study were 38 patients diagnosed with haematogenous infective discitis. Of the 38 patients, 7 had tubercular infection, 1 fungal infection and 30 pyogenic discitis. Four patients were excluded because the second PET/CT scan was not performed. Thus 34 patients (18 women, mean age 64 years) were analysed. All the patients included underwent a FDG PET/CT scan and determination of CRP level at baseline and again 2 to 4 weeks after the start of therapy. The PET results in terms of SUV of the first and second scans (SUV1 and SUV2) and delta-SUVmax were compared to the inflammatory indexes and clinical status during therapy.

Results

The mean SUVmax at diagnosis was 8.6 ± 3.7. The mean CRP level at diagnosis was 3.8 ± 3.8 mg/dl. A progressive clinical response was seen in 26 patients and 8 patients showed no response. SUV1 was not correlated with the baseline CRP level (CRP1, p = 0.7) and SUV2 was not correlated with the CRP level at the time of the second scan (CRP2, p = 0.4). In responders, SUV2 and CRP2 were significantly lower than SUV1 and CRP1 (p < 0.0001 and p = 0.001, respectively). ROC curves for delta-SUVmax showed a sensitivity of 82 % and a specificity of 82 % with a cut-off of 34 %. ROC curves for SUV2 showed a sensitivity of 83 % and a specificity of 46 % with a cut-off of 6.4. ROC curves for delta-CRP showed a sensitivity of 67 % and a specificity of 89 % with a cut-off of 74 %. ROC curves for CRP2 showed a sensitivity of 65 % and a specificity of 70 % with a cut-off of 0.7 mg/dl. No statistically significant difference was found between delta-SUVmax AUC and delta-CRP AUC (p = 0.5).

Conclusion

Delta-SUVmax provided a higher sensitivity and specificity for identifying responders. SUV2 provided comparable sensitivity, but significantly lower specificity. CRP level performed less well for identifying responders. There was no significant difference in the global performance of the two tests (delta-SUVmax AUC and delta-CRP AUC). However, the higher sensitivity of delta-SUVmax for the early identification of responders may have an important clinical impact in guiding antibiotic therapy especially in patients with a noninformative CRP test at diagnosis.
Literatur
1.
Zurück zum Zitat Kirkman MA, Sridhar K. Posterior listhesis of a lumbar vertebra in spinal tuberculosis. Eur Spine J. 2011;20(1):1–5.PubMedCrossRef Kirkman MA, Sridhar K. Posterior listhesis of a lumbar vertebra in spinal tuberculosis. Eur Spine J. 2011;20(1):1–5.PubMedCrossRef
2.
Zurück zum Zitat Viale P, Furlanut M, Scudeller L, Pavan F, Negri C, Crapis M, et al. Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. Int J Antimicrob Agents. 2009;33(4):379–82.PubMedCrossRef Viale P, Furlanut M, Scudeller L, Pavan F, Negri C, Crapis M, et al. Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. Int J Antimicrob Agents. 2009;33(4):379–82.PubMedCrossRef
3.
Zurück zum Zitat Rimmele T, Boselli E, Breilh D, Djabarouti S, Bel JC, Guyot R, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother. 2004;53(3):533–5.PubMedCrossRef Rimmele T, Boselli E, Breilh D, Djabarouti S, Bel JC, Guyot R, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother. 2004;53(3):533–5.PubMedCrossRef
4.
Zurück zum Zitat Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(12):4011–7.PubMedCrossRef Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(12):4011–7.PubMedCrossRef
5.
Zurück zum Zitat Tascini C, Tagliaferri E, Di Paolo A, Ciofi L, Del Tacca M, Lambelet P, et al. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections. J Chemother. 2009;21(4):421–5.PubMed Tascini C, Tagliaferri E, Di Paolo A, Ciofi L, Del Tacca M, Lambelet P, et al. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections. J Chemother. 2009;21(4):421–5.PubMed
6.
Zurück zum Zitat Garazzino S, Aprato A, Baietto L, D’Avolio A, Maiello A, De Rosa FG, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet. 2008;47(12):793–805.PubMedCrossRef Garazzino S, Aprato A, Baietto L, D’Avolio A, Maiello A, De Rosa FG, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet. 2008;47(12):793–805.PubMedCrossRef
7.
Zurück zum Zitat Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65 Suppl 3:iii11–24.PubMedCrossRef Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65 Suppl 3:iii11–24.PubMedCrossRef
8.
Zurück zum Zitat Zilkens KW, Peters KM, Schwanitz BM. New inflammation markers for early detection of spondylodiscitis. Eur Spine J. 1992;1(3):152–5.PubMedCrossRef Zilkens KW, Peters KM, Schwanitz BM. New inflammation markers for early detection of spondylodiscitis. Eur Spine J. 1992;1(3):152–5.PubMedCrossRef
9.
Zurück zum Zitat Ohtori S, Suzuki M, Koshi T, Yamashita M, Yamauchi K, Inoue G, et al. 18F-fluorodeoxyglucose-PET for patients with suspected spondylitis showing Modic change. Spine. 1976;35(26):E1599–603.CrossRef Ohtori S, Suzuki M, Koshi T, Yamashita M, Yamauchi K, Inoue G, et al. 18F-fluorodeoxyglucose-PET for patients with suspected spondylitis showing Modic change. Spine. 1976;35(26):E1599–603.CrossRef
10.
Zurück zum Zitat Albert H, Pedersen H, Manniche C, Hoilund-Carlsen PF. PET imaging in patients with Modic changes. Nuklearmedizin. 2009;48(3):110–2.PubMed Albert H, Pedersen H, Manniche C, Hoilund-Carlsen PF. PET imaging in patients with Modic changes. Nuklearmedizin. 2009;48(3):110–2.PubMed
Metadaten
Titel
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis
verfasst von
Cristina Nanni
Luca Boriani
Caterina Salvadori
Eleonora Zamparini
Giada Rorato
Valentina Ambrosini
Alessandro Gasbarrini
Fabio Tumietto
Francesco Cristini
Luigia Scudeller
Stefano Boriani
Pierluigi Viale
Stefano Fanti
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2179-8

Weitere Artikel der Ausgabe 10/2012

European Journal of Nuclear Medicine and Molecular Imaging 10/2012 Zur Ausgabe